Year :

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

SOMERSET, N.J.—(BUSINESS WIRE) — February 18, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, […]

Feb 18, 2022

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

SOMERSET, NJ — (BUSINESS WIRE) — February 15, 2022 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that on Friday, February 11, 2022, the company was informed by the U.S Food and Drug Administration (FDA) via email communication that its Phase 1 clinical […]

Feb 15, 2022

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

SOMERSET, N.J.— (BUSINESS WIRE) —February 11, 2022— Legend Biotech Corporation(NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen […]

Feb 11, 2022

Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.— (BUSINESS WIRE) —January 4, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, will deliver the company presentation on Tuesday, January 11, 2022 at […]

Jan 04, 2022

Legend Biotech Announces Closing of Global Strategic LCAR-B38M CAR-T Cell Immunotherapy Collaboration with Janssen

Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen […]

Dec 22, 2017

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.